Alembic Pharma gets USFDA nod for Valganciclovir oral solution

Alembic Pharmaceuticals secures USFDA approval for Valganciclovir oral solution. This clears the way for the company to launch a generic version of the drug in the US market. Valganciclovir is used to treat cytomegalovirus (CMV) infection in transplant patients. The approval enhances Alembic’s portfolio in the key US generics segment.
📊 STOCKS: $ALPH | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA